MADDEN SECURITIES Corp Makes New Investment in GSK plc (NYSE:GSK)

MADDEN SECURITIES Corp acquired a new position in shares of GSK plc (NYSE:GSK) during the 4th quarter, according to its most recent 13F filing with the SEC. The firm acquired 87,430 shares of the pharmaceutical company’s stock, valued at approximately $2,957,000. GSK accounts for 1.2% of MADDEN SECURITIES Corp’s investment portfolio, making the stock its 22nd biggest position.

A number of other institutional investors and hedge funds have also bought and sold shares of the company. Savant Capital LLC increased its stake in shares of GSK by 44.5% during the fourth quarter. Savant Capital LLC now owns 8,126 shares of the pharmaceutical company’s stock valued at $275,000 after buying an additional 2,504 shares during the period. Miller Howard Investments Inc. NY bought a new position in shares of GSK in the 4th quarter worth $23,366,000. Stephens Inc. AR grew its stake in GSK by 10.4% in the fourth quarter. Stephens Inc. AR now owns 36,932 shares of the pharmaceutical company’s stock valued at $1,249,000 after purchasing an additional 3,472 shares during the last quarter. Stockman Wealth Management Inc. grew its position in shares of GSK by 3.7% in the 4th quarter. Stockman Wealth Management Inc. now owns 217,200 shares of the pharmaceutical company’s stock worth $7,346,000 after buying an additional 7,683 shares during the last quarter. Finally, Robinson Value Management Ltd. boosted its stake in GSK by 2.7% in the fourth quarter. Robinson Value Management Ltd. now owns 57,101 shares of the pharmaceutical company’s stock valued at $1,931,000 after acquiring an additional 1,494 shares in the last quarter. 15.74% of the stock is owned by institutional investors.

GSK Stock Up 1.1 %

Shares of GSK stock opened at $36.45 on Tuesday. GSK plc has a fifty-two week low of $31.72 and a fifty-two week high of $45.92. The firm has a market capitalization of $75.53 billion, a PE ratio of 22.92, a P/E/G ratio of 1.42 and a beta of 0.64. The company has a debt-to-equity ratio of 1.12, a quick ratio of 0.53 and a current ratio of 0.78. The stock’s 50-day simple moving average is $34.25 and its 200-day simple moving average is $37.55.

GSK (NYSE:GSK) last issued its quarterly earnings results on Wednesday, February 5th. The pharmaceutical company reported $0.59 earnings per share for the quarter, topping the consensus estimate of $0.44 by $0.15. GSK had a net margin of 8.13% and a return on equity of 48.59%. Equities analysts expect that GSK plc will post 4.07 earnings per share for the current year.

GSK Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, April 10th. Investors of record on Friday, February 21st will be issued a dividend of $0.3932 per share. This represents a $1.57 annualized dividend and a dividend yield of 4.31%. The ex-dividend date of this dividend is Friday, February 21st. This is a boost from GSK’s previous quarterly dividend of $0.39. GSK’s dividend payout ratio (DPR) is 98.74%.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on the company. Guggenheim downgraded GSK from a “buy” rating to a “neutral” rating in a research report on Thursday, October 31st. StockNews.com upgraded GSK from a “buy” rating to a “strong-buy” rating in a research note on Friday. Deutsche Bank Aktiengesellschaft lowered GSK from a “buy” rating to a “hold” rating in a research note on Friday, November 15th. Finally, Jefferies Financial Group lowered shares of GSK from a “buy” rating to a “hold” rating and decreased their price objective for the company from $53.00 to $39.50 in a research report on Tuesday, November 12th. Six analysts have rated the stock with a hold rating and four have assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $43.25.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.